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Abstract MMPs constitute a family of endopeptidases implicated in numerous
physiological and pathological tissue remodeling events. During
development, MMPs are essential for organogenesis, vascular system
development and maturation. Their expression is crucial for tissue repair
during injury and plays an important role in vascular response to injuries
or assaults. MMPs are mainly expressed by stromal cells including
fibroblasts, inflammatory and endothelial cells. Their expression is
highly correlated with endothelial tube formation and vessel maturation
during development and tissue repair. However, aberrant extracellular
and perivascular stroma remodeling mediated by these enzymes alters
vessel function in vascular diseases. In this review, we will focus on
mechanistic new insights on MMP action in tissue remodeling observed
during vascular pathologies. Such alterations are associated with cancer
progression and vascular diseases leading to vascular wall destabilization
and dysfunctions in diabetic retinopathy, hypertension, aneurism rupture
and arthrosclerosis. As MMPs are major proteolytic pathwayregulators
in tissue remodeling, we will shed light on molecular and cellular events
that are altered by their function in vascular wall.
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514.1 Introduction
6Blood vessels are highly organized structures in which the extracellular matrix
7(ECM) of the vessel wall and the perivascular interstitium contribute substantially
8to their diverse functions. Synthesis and degradation of ECM components in
9vascular wall or perivascular stroma are tighly controlled mechanisms. Matrix
10metabolism perturbation is sufficient to significantly affect vascular system physi-
11ology leading to several vascular disorders including diabetic retinopathy (Turley
122001), hemorrhagic telangiectasia (Arteaga-Solis et al. 2000), hypertensive heart
13diseases (Morwood and Nicholson 2006), atherosclerosis and fibrosis (Diez 2007;
14Radisky et al. 2007). Vascular abnormalities are also associated with cancer
15progression and metastatic dissemination (Berk et al. 2007). The ECM in the
16vascular wall contains a variety of molecules including collagens, elastic fibers,
17glycoproteins and proteoglycans that provide structural and mechanical support to
18cells. Vascular cells are connected to these structural matrix components by cell
19surface receptors of integrins and non-integrins types (Davis and Senger 2008).
20Matrixreceptor interactions influence vascular cell shape, behavior and response to
21cytokines and growth factors (Boudreau and Jones 1999). Alterations of vessel
22matrix have thus profound impact on blood vessel integrity affecting thereby the
23extravasation of fluids and plasma proteins into the interstitium (Wiig et al. 2008).
24ECM molecules play a major role of in maintaining mature tubular structures in
25vascular and lymphatic systems (Bergers and Benjamin 2003; Oliver and Detmar
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26 2002). For instance, genetic studies show that mutations in COL3A1 leads to
27 Ehlers-Dahlos syndrome type IV characterized predominantly by arterial dilation
28 and rupture (Arteaga-Solis et al. 2000). On other hand, a mutation in the Fibrillin-1
29 (FBN1) gene in Marfan syndrome, results in deficiency of elastic fibers that regulate
30 cell attachment in vessel walls to the neighboring ECM (Neptune et al. 2003). Thus
31 proper metabolism, assembly in vascular tissues regulates maintenance of tissue
32 homeostasis. Functional and structural vascular remodeling involve several
33 enzymes among which MMPs produced by endothelial, inflammatory, or malignant
34 cells are key players. The present review will describe the contribution of MMPs in
35 the remodeling of collagens that are essential vessel components. Understanding
36 the complex role of MMPs in vessel wall assembly and functions in homeostasis or
37 diseases is mandatory to provide new therapy to maintain vessel stability and proper
38 function.
39 14.2 Collagenolytic Activities of MMPs
40 MMPs are a family of zinc-dependent endopeptidases composed of 24 currently
41 known human enzymes that share several functional domains. MMPs are often
42 referred to soluble (MMPs) or membrane type-MMPs (MT-MMPs) that are
43 anchored to the cell surface through transmembrane domain or glycosylphosphati-
44 dylinositol (GPI) linker. For a description of the structure, function and regulation
45 of MMPs and MT-MMPs, the reader is referred to previous reviews (Kessenbrock
46 et al. 2010; Page-McCaw et al. 2007; Sohail et al. 2008; Sounni and Noel 2005;
47 Strongin 2010; Zucker et al. 2003). Interstitial collagenases are the only known
48 mammalian enzymes able of degrading triple-helical fibrillar collagen into distinc-
49 tive tropocollagen A (TCA) (3/4) and (TCB) (1/4) fragments as a consequence of a
50 specific proteolysis of all three α-chains at a single locus three-quarters from the
51 N-terminus. Collagenolytic MMPs include soluble MMPs (MMP1, MMP8,
52 MMP13) and the membrane-associated MMP14/MT1-MMP. More recently,
53 MMP2 has been identified as an interstitial collagenase that can cleave native
54 type I collagen in a distinctive way from other collagenases without generating
55 the classical TCA fragment (Egeblad et al. 2007). MMP-2 and MMP-9 (initially
56 referred to as gelatinase A and gelatinase B, respectively) cleave type IV collagen
57 present in basement membrane and the degradation products generated by the
58 action of interstitial collagenases. These MMPs produced by endothelial cells,
59 fibroblasts, smooth muscle cells (VSMCs) and inflammatory cells play pivotal
60 roles in multiple physiological and pathological processes involving extensive
61 and aberrant collagenolysis (Fig. 14.1). Latest technological progresses have obvi-
62 ously advanced our consideration of MMPs as key regulators that operate in
63 complex cellular and molecular networks. In addition to the mentioned
64 collagenolytic activities, MMPs contribute to the proteolytic cleavage of an increas-
65 ing repertoire of substrates that includes at least, almost all ECM components,
66 chemokines/cytokines, growth factors and cell surface receptors (Butler and
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67Overall 2009; Hu et al. 2007). Under normal conditions, MMP activities are
68controlled through transcriptional regulation, activation of pro-MMP precursor
69zymogens and inhibition by physiological tissue inhibitor of matrix metallopro-
70teinases (TIMPs) that bind MMP in a 1:1 stoichiometry (Kessenbrock et al. 2010;
71Lopez-Otin and Overall 2002). Four TIMPs have been identified in vertebrates and
72their expression is regulated during development and tissue remodeling (Nagase
73et al. 2006). More recently some MMPs and TIMPs were described as targets of
74epigenetic regulation via CpG methylation and histones modifications (Chernov
75et al. 2009; Liu et al. 2007; Pulukuri et al. 2007).
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Fig. 14.1 MMP effects on vessel function and maturation. MMPs are produced in perivascular
stroma by endothelial (EC), pericyte (PC) inflammatory cells, and fibroblasts (I). They regulate
vessel function and maturation through different mechanisms which relay on their proteolytic
activity. MMPs increase growth factor availability in perivascular stroma, unmask cryptic sites
within extracellular matrix molecules and generate angiogenesis inhibitor form basement mem-
brane (BM) collagens (II). MMPs activity controls the vascular homeostasis and regulates vessel
permeability and leakage in vascular diseases (III)
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76 14.3 MMP-Mediated Collagen Remodeling in Vessel
77 Structure and Functions
78 MMPs contribute to perivascular matrix remodeling during normal angiogenesis
79 (Ucuzian and Greisler 2007). In pathological conditions, the vascular wall and
80 perivascular interstitium are exposed to intensive MMP-mediated remodeling that
81 can create a less restrictive microenvironment. A sustained MMP activity is
82 associated with several vascular pathologies including aneurysm, atherosclerosis,
83 hypertension and restinosis (Mott and Werb 2004; Page-McCaw et al. 2007).
84 MMP-mediated collagen remodeling can regulate tissue architecture through dif-
85 ferent mechanisms. They can generate extracellular space for cell migration and
86 unmask cryptic sites within ECM molecules modifying thereby cell to matrix
87 adhesion. By promoting the release of matrix-associated growth factors or
88 cytokines, they modulate the activity or bioavailability of signaling molecules
89 during vascular response to physiological or pathological stimuli (Kessenbrock
90 et al. 2010; Page-McCaw et al. 2007). MMP activities result also in the generation
91 of matrix fragments displaying novel biological activity (Kessenbrock et al. 2010;
92 Page-McCaw et al. 2007; Rundhaug 2005). It is now well recognized that collagen
93 proteolysis may release a number of endogenous angiogenesis inhibitors, including
94 type IV (arresten, canstatin, tumstatin), type V (restin) and type XVIII (endostatin,
95 neostatins) collagen fragments among other fragments of ECM proteins that may
96 display anti-angiogenic activity (Egeblad and Werb 2002; Kojima et al. 2008;
97 Nyberg et al. 2005). These angio-inhibitory fragments regulate primarily endothe-
98 lial cell proliferation and apoptosis by interfering with integrins. The contribution
99 of such endogenous inhibitors in human pathologies is supported by the role played
100 by endostatin in choroidal neovascularization (CNV) associated to age-related
101 macular degeneration (AMD), the leading cause of blindness in elderly patients
102 (Noel et al. 2007). MMPs release and activate endostatin from collagen XVIII
103 present in vascular basement membranes and Bruch membrane (Ferreras
104 et al. 2000; Zatterstrom et al. 2000). Endostatin levels are decreased in human
105 eyes with AMD, and its deficiency was suggested to predispose to CNV formation
106 (Bhutto et al. 2004). Accordingly, both external delivery of endostatin and endoge-
107 nous endostatin inhibits experimental CNV (Marneros et al. 2007).
108 14.3.1 Type IV Collagen Remodeling
109 Type IV collagen is the main component of vascular basement membrane that
110 forms a mesh-like structure with other molecules such as laminin, heparan sulfate
111 proteoglycans, fibronectin and entactin. In addition to the release of endogenous
112 angiogenic inhibitor (Fig. 14.1), specific cryptic type IV collagen epitopes can be
113 exposed upon proteolysis. For instance, a cryptic site hidden within the three-
114 dimensional structure of type IV collagen is exposed by MMP2 and promotes
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115in vivo angiogenesis (Xu et al. 2001). The recognition of a cryptic epitope (HU177)
116present exclusively in type IV collagen by a specific mouse antibody (HUIV26)
117inhibits endothelial cell proliferation and differentiation into tubule-like structures
118(Cretu et al. 2007). Interference with this epitope results in the expression of cyclin-
119dependent kinase (CDK) inhibitor p27kip1 in endothelial cells (Cretu et al. 2007).
120Cryptic activities embedded within intact type IV collagen molecules are also
121unmasked as a consequence of MT1-MMP, MT2-MMP and MT3-MMP action
122during morphogenesis (Rebustini et al. 2009). In eyes, exposure of cryptic collagen
123type IV epitopes is associated with increased CNV incidence. In line with this
124finding, the humanized antibody H8 directed against a cryptic collagen type IV
125epitope inhibits CNV progression (Gocheva et al. 2006).
12614.3.2 Type I Collagen Remodeling
127Type I collagen fibrils, the most abundant extracellular matrix (ECM) proteins in
128perivascular stroma (Di Lullo et al. 2002) is a heterotrimer molecule composed of
129two α1(I) and one α2(I) chains encoded by two separate genes: Col1a1 and Col1a2
130(Shoulders and Raines 2009). Type I collagen remodeling in perivascular stroma
131represents an important step in cell migration and endothelial cell reorganization
132into tubular structure during normal and pathological angiogenesis. We have
133previously investigated the role of type I collagen proteolysis in perivascular stroma
134in transgenic mice carrying a mutation in colla1 gene (Col1a1r/rmice) that renders
135type I collagen resistant to collagenase-mediated cleavage into the TCA and TCB
136fragments (Liu et al. 1995). These transgenic mice (Col1a1r/r) showed a dramatic
137reduction in steady state vascular leakage measured by plasma extravasation after
138quantification of Evans blue dye in interstitial space of skin tissue. Vessel structure
139analysis showed that these mice have reduced number of vascular openings within
140vessel wall and failed to develop normal vascular response after chemical stimula-
141tion of skin due to the lack of collagen remodelling in the perivascular stroma
142(Sounni et al. 2010a).
143These data suggest that type I collagen remodelling is an important step in
144vascular response to tissue injuries and damage. Type I collagen is classically
145cleaved into characteristic TCA and TCB fragments by MMP1, MMP8, MMP13
146and MT1-MMP (also called MMP14) (Ohuchi et al. 1997). Perturbations in colla-
147gen type I assembly, remodeling and synthesis is associated with increased tissue
148alterations such as atherosclerosis, fibrosis, and tumor. Type I collagen cleavage by
149MT1-MMP at endothelial cell surface stimulates migration, guidance and organi-
150zation of endothelial cells into tubular structures (Collen et al. 2003). In the tumor
151microenvironment, type I collagen remodeling by MT1-MMP enables cancer cells
152to escape the mechanical barriers that confine them to collagen matrix and
153stimulates tumor growth in vivo (Hotary et al. 2003). The generation of
154MT1-MMP knockout mice delineated the role of MT1-MMP in collagen
155remodeling during development. Indeed, Mt1-mmp/ mice exhibit skeletal
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156 defects with craniofacial abnormalities, osteopenia and angiogenesis (Holmbeck
157 et al. 1999; Zhou et al. 2000). MT1-MMP not only acts as an interstitial collage-
158 nase, but is also the main activator of pro-MMP2 at the cell surface (Sato
159 et al. 1994; Sounni et al. 2010b). Although MMP2 exhibits gelatinolytic activity,
160 it does not cleave type I collagen in a similar manner than do the classical interstitial
161 collagenases. Nevertheless, MMP2 contribution in interstitial collagen remodeling
162 has been evidence in vivo, by intercrossing Col1a1r/r mice with Mmp2/ mice
163 and generation of double transgenic Col1a1r/r/Mmp2/ mice in FVBn strain.
164 Intriguingly, these Col1a1r/r/Mmp2/ mice display severe developmental
165 defects resembling the skeletal defect syndromes found in MMP2-null patients
166 with inactivating mutations in Mmp2 gene (Egeblad et al. 2007; Martignetti
167 et al. 2001). While Mmp2/ mice have only mild aspects of these abnormalities,
168 collagen metabolism perturbation in double transgenic Col1a1r/r/Mmp2/ mice
169 increases alteration phenotype of Mmp2/ mice, suggesting that MMP2 is
170 important in type I collagen remodelling through a mechanism different to that
171 used by classical interstitial collagenases (MMP1, MMP8, MMP13 and
172 MT1-MMP).
173 14.4 MMP-Mediated Proteolysis of Endothelial Cell-Cell
174 Contact Molecules
175 The functional barrier properties of blood vessels are not only dependent on
176 endothelial cell interactions with underlying basement membrane, but also on the
177 resistance and cohesive features of endothelial cells. Cell-cell cohesion involves the
178 adherent complex vascular endothelial-cadherin (VE-cadherin), the inter-
179 endothelial cell tight junction proteins (TJPs) and junctional adhesion molecules
180 (JAMs). TJPs consist of three major families of transmembrane proteins, zonula
181 occludens-1 (ZO-1), claudins and occludins (Matter and Balda 2003). MMP con-
182 tribution in endothelial cell-cell contact regulation is well documented in several
183 experimental model of cerebral ischemia (Hawkins et al. 2007; Yang et al. 2007b).
184 For instances, MMP activity has been correlated with the breakdown of tight
185 junctions leading to increased blood-brain barrier (BBB) permeability, ischemia,
186 diabetic retinopathy, vericosis and atherosclerosis (Fujimoto et al. 2008; Hu
187 et al. 2007; Navaratna et al. 2007; Yang et al. 2007a). There is direct evidence
188 that MMP2, MMP9 and MT1-MMP activities induce changes in TJPs (claudin-5
189 and occludin) leading to BBB disruption of rat brain (Yang et al. 2007b). Moreover,
190 MMP-9 gene deletion reduced ZO-1 degradation associated with attenuation of
191 BBB leakage (Asahi et al. 2001). Accordingly, TIMP-1 gene deletion accelerates
192 ZO-1 degradation through increased MMP-9 activity in cerebral ischemia
193 (Fujimoto et al. 2008). Another report supports also the role of MMP2, MMP3
194 and MMP9 in TNF alpha-induced alteration of the bloodcerebrospinal fluid barrier
195 in vitro (Zeni et al. 2007).
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196The role of MMPs in the maintenance of systemic vessel integrity and
197remodeling in diabetic retinopathy has been linked to the breakdown of occludin
198(Giebel et al. 2005) and VE-cadherin (Navaratna et al. 2007). Beside MMPs, a
199number of recent findings point out to the role of ADAMs in endothelial adherent
200junction. For instance, proteolytic activity of ADAM10 induces removal and
201shedding of VE-cadherin from endothelial cell surface, which in turn regulates
202vascular permeability and inflammation process associated with atherosclerosis
203(Schulz et al. 2008). ADAM-10 effect on endothelial cell permeability and T cell
204transmigration involve VEcadherin ectodomain cleavage generating a soluble
205fragment, while the remaining carboxyterminal membrane bound portion is further
206cleaved by γ-secretase. ADAM-10-mediated VEcadherin cleavage is induced by
207thrombin activation of endothelial cells, Ca2+ influx, as well as induction of
208apoptosis by staurosporine treatment. Inhibition of ADAM-10 by GI254023X
209decreased endothelial cell permeability and transmigration of T cells.
210Tight junction proteins such as JAM-A, JAM-B, and JAM-C regulate leukocyte-
211endothelial cell interaction through their ability to undergo heterophilic binding
212with leukocyte integrins LFA-1, VLA-4, and Mac1, respectively (Ebnet et al. 2004;
213Keiper et al. 2005). In addition, their junctional localization in endothelial cells
214regulates endothelial barrier permeability through the control of actomyosin-
215dependent contractility and VE-catherin-mediated cell-cell contact in a Rap1-
216dependent manner (Orlova et al. 2006). A recent study suggests that MMPs could
217be involved in the generation of a soluble JMA-C form (sJMA-C) appearing as a
218potent proangiogenic mediator of pathological angiogenesis (Rabquer et al. 2010).
219However, the individual MMP or ADAM involved in this process remains to be
220identified and it is not clear whether this process could affect vascular leakage and
221permeability in tumors.
222In addition to these effects on vascular permeability, MMP contribution on
223vascular contraction is documented. MMPs affect membrane Ca2+ and/or K+
224channel activity, likely through an interaction with αvβ3 integrin (Miyazaki
225et al. 2011). MMP inhibitors block Ca2+ entry and vascular contraction (Chew
226et al. 2004). During varicose vein formation, MMP2 induces venous dilation via
227hyperpolarization and activation of K+ channels (Raffetto et al. 2007). MMP2 also
228regulates Ca(2+) entry into smooth muscle (VSM) which in turn causes hyperpo-
229larization and relaxation of venous segments (Raffetto et al. 2010).
23014.5 MMP-Mediated Vessel Maturation Through Pericyte
231Recruitment
232During the process of angiogenesis, vascular mural cells (VSMCs or pericytes) are
233recruited to the newly formed blood vessels where they contribute to vessel
234maturation. Pericytes, the mural cells of microvessels, extend long cytoplasmic
235processes on the abluminal surface of the endothelial cells, making tight contacts
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236 that are important for blood vessel stabilization. They are important in the forma-
237 tion and/or remodeling of perivascular ECM including the vascular basement
238 membrane, and they regulate vessel function (Armulik et al. 2005; Diaz-Flores
239 et al. 2009; von Tell et al. 2006). Pericytes control vessel permeability through their
240 contractile properties and regulate blood flow in vessels, and consequently they
241 could influence delivery of drug to tumors (Feron 2004; Raza et al. 2010). Pericytes
242 are recruited in newly formed vessels through several molecular axis including
243 PDGFB/PDGFR-β, S1P/endothelial differentiation gene-1 (EDG-1), Ang1/Tie2
244 and TGF-β/activine-like kinase receptor (ALK5) (Gerhardt and Semb 2008; Jain
245 2003; Park et al. 2009). For instance, double deletion of PDGFB and PDGFR-β in
246 mice lead to lethal microhaemorages due to lack of vessel coverage by pericytes
247 (Lindahl et al. 1997). Increasing evidences demonstrate that MMPs affect vessel
248 coverage through different mechanisms. MMPs induce pericytes migration through
249 ECM degradation, but also regulate their differentiation and recruitment from bone
250 marrow through the release of angiogenic factors sequestered in the ECM
251 (Chantrain et al. 2006; Sounni and Noel 2005). MMP inhibition in different
252 experimental tumor models of melanoma and neuroblastoma reduced pericyte
253 recruitment and decreased tumor vessel perfusion (Chantrain et al. 2004; Noel
254 et al. 2008; Spurbeck et al. 2002). Indeed, MMP3 and MMP7 promote pericyte
255 recruitment and vessel maturation through shedding of membrane bound HB-EGF
256 and signaling in vivo (Suzuki et al. 1997). If inflammatory cell-derived MMP9
257 promotes tumor angiogenesis by releasing ECMbound VEGF (Bergers et al. 2000;
258 Huang et al. 2002), pericyte coverage along tumor microvessels is directly affected
259 in MMP9 deficient mice xenotransplanted with human neuroblastoma. Interest-
260 ingly, bone marrow transfer from wild type mice to MMP9/ mice completely
261 restores tumor vessels maturation (Chantrain et al. 2004). These data suggest that
262 MMP9 is an important regulator of pericyte recruitment from bone marrow.
263 A number of studies demonstrated that TGFβ promotes investment and differ-
264 entiation of peri-vascular cells leading to vessel stabilization. TGFβ has been
265 implicated as a regulator of vascular integrity (Gleizes and Rifkin 1999; Pepper
266 1997; Tuxhorn et al. 2002), vasculogenic and angiogenic processes (Dickson
267 et al. 1995; Pepper 1997), endothelial and mural cell proliferation and/or differen-
268 tiation (Sato 1995; Vinals and Pouyssegur 2001; Yan and Sage 1998). Moreover,
269 vascular abnormalities have been described in TGFβ null mice (Dickson
270 et al. 1995). In VSMCs, TGFβ can bind to ALK5 and activate SMADs 2 and 3 to
271 promote cell differentiation, increase contractility and ECM synthesis (Chan
272 et al. 2010; Kano et al. 2007). Alternatively, TGFβ may also promote vascular
273 stability by increasing the expression of factors such as Ang-1 that stabilizes
274 vasculature by acting on adjacent endothelial cells (Thurston et al. 1999). Moreover
275 TGFβ-induced fibroblast or smooth muscle cell (SMC) contractility could increase
276 tension on ECM leading to increased interstitial fluid pressure to further restrict
277 capillary outflow (Heldin et al. 2004). The control of TGFβ bioavailability is a post-
278 translational pathway subject to regulation by MMP activity. MMP2, -3, -7 induce
279 in vitro the release of TGFβ1 from decorin, a proteoglycan that sequester TGFβ in
280 the ECM (Imai et al. 1997). Furthermore, studies on MT1-MMP revealed its
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281important role in the activation of proTGFβ in vivo and control of vascular
282homeostasis (Sounni et al. 2010a; Tatti et al. 2008).
28314.6 MT1-MMP: A Key Regulator of Vessel Function and
284Physiology
285MT1-MMP is likely the most important MMP regulating endothelial cell functions.
286Among all the MMPs knockout mice generated, Mt1-mmp mice only showed
287impaired angiogenesis leading to delayed ossification and consequently a severe
288skeletal defect (Sounni and Noel 2005; Zhou et al. 2000). Beside its role in ECM
289remodeling, MT1-MMP promotes endothelial cell migration, lumen formation and
290vascular guidance tunnels in collagen matrices (Stratman et al. 2009). It stimulates
291angiogenesis in fibrin gel more efficiently than other proteases (Collen et al. 2003;
292Hiraoka et al. 1998; Hotary et al. 2002). MT1-MMP proangiogenic capacities in
293both physiological and pathological conditions are related to several mechanisms
294including: (1) ECM remodeling (Hotary et al. 2003), (2) transcriptional and post-
295translational control of VEGF expression and biodiponibility (Deryugina
296et al. 2002; Eisenach et al. 2010; Sounni et al. 2002, 2004), (3) interaction with
297cell surface molecules, such as CD44 (Kajita et al. 2001) and sphingosine 1-
298phosphate (S1P) (Langlois et al. 2004), (4) hematopoietic progenitor cells mobili-
299zation (Vagima et al. 2009), or (5) degradation of anti-angiogenic factors such as
300decorin in cornea (Mimura et al. 2009). Furthermore, a number of recent reports
301have shed light of the role of MT1-MMP in TGFβ signaling during angiogenesis
302and vessel maturation (Hawinkels et al. 2010; Sounni et al. 2011; Tatti et al. 2008).
303Spatial and temporal MT1-MMP expression during angiogenesis has been
304recently followed in the transgenic Mt1-mmp+/LacZ mice (Yana et al. 2007).
305MT1-MMP expression at leading edges of newly developed vessels is a result of
306coordinated crosstalk between endothelial cells and VSMCs during vascular matu-
307ration step of angiogenesis. Works by Lehti and colleagues (Lehti et al. 2005)
308showed that MT1-MMP is important for PDGFR-β processing propagating signal-
309ing through VSMCs and promoting cell migration. Vasculature of Mt1-mmp/
310mice brain have a sever reduction in mural cell density and abnormal vessel
311morphology, due to impaired PDBFB/PDGFR-β AU2signaling in VSMCs. Moreover,
312MT1-MMP induces VSMC dedifferentiation and acquisition of migratory and
313invasive phenotype during vascular injury through low density lipoprotein (LDL)
314receptor-related protein (LRP) proteolysis that promotes signaling through PDGFB/
315PDGFR-β axis (Lehti et al. 2009). In addition, MT1-MMP regulates signaling in
316vascular cells through several mechanisms. It cooperates with platelet-derived S1P
317to induce endothelial cell migration and morphogenic differentiation (Langlois
318et al. 2004). It regulates signaling of the advanced glycation end products (AGE)/
319a receptor for AGE (RAGE) axis in vascular disorders associated with diabetic
320(Kamioka et al. 2011). Furthermore, a recent report shows that MT1-MMP activity
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321 at endothelial cell surface mediates Tie-2 shedding and regulates angiopoietin1
322 (Ang1)/Tie-2-associated signaling pathways (Onimaru et al. 2010). It is generally
323 accepted that Ang1-mediated activation of Tie-2 promotes vascular stabilization
324 and quiescence, whereas Ang2 acts in opposition to Ang1 to facilitate VEGF
325 mediated angiogenesis (Gale and Yancopoulos 1999). MT1-MMP interference
326 with Ang1-Tie2 reinforces its role in vessel activation a well known process widely
327 attributed to VEGF (Findley et al. 2007).
328 Recently, we provided evidence for MT1-MMP activity in perivascular stroma
329 in vivo and regulation of vascular stability and permeability (Sounni et al. 2010a).
330 By assessing the effect of MMP deletion on vessel permeability and leakage applied
331 to the skin ofMmp2/, Mmp9/, Mmp8/ andMmp13/ and Mt1-mmp/
332  mice, we found that except Mt1-mmp/ mice, induced or steady state leakage
333 were not affected in these mice and Mt1-mmp/ mice have a higher steady-state
334 vascular leakage. Moreover, prior treatment of wild-type mice with broad spectrum
335 MMP inhibitor GM6001 (Ilomasta, Galardin) significantly increases vascular leak-
336 age in vivo. These data indicate that MMP inhibition renders vessels more suscep-
337 tible to induced acute leakage and implies a link between basal MMP activity and
338 vessel function. A link between MT1-MMP and TGFβ pathway in vascular homeo-
339 stasis maintenance has been demonstrated by our finding on MT1-MMP-mediated
340 control of TGFβ bioavailability and signaling through ALK5 (TGFR-I) in vascular
341 wall in vivo (Sounni et al. 2010a). Interestingly, ALK5 inhibitor increased in vivo
342 vascular leakage and enhanced macromolecule delivery and biodistribution in two
343 syngenic model of skin carcinoma (K14-HPV16 transgenic mice) and mammary
344 adenocarcinoma (MMTV-PyMT mice). These data shed light on MT1-MMP con-
345 tribution in TGFβ-controlled vascular homeostasis and remodeling. They further
346 indicate that TGFβ and/or MT1-MMP-selective antagonists may enhance vascular
347 leakage and therapeutic delivery to tissues where hemodynamic limits efficient
348 drug delivery. Recently, MT1-MMP-dependent shedding of endoglin from endo-
349 thelial cell surface has been documented and associated to angiogenesis inhibition
350 in vitro. The study correlates a decrease of circulating endoglin with colorectal
351 cancer and suggests that released soluble endoglin by MT1-MMP could acts as
352 decoy for TGFβ that may blocks downstream signaling in endothelial cells and
353 inhibits tumor angiogenesis (Hawinkels et al. 2010). However, MT1-MMP levels in
354 these samples were not correlated with the level of soluble endoglin and further
355 studies are required to support the controversial anti-angiogenic effect of
356 MT1-MMP in vivo. The effect of MT1-MMP interaction with TGFβ signaling on
357 angiogenesis in vivo, appears therefore as a complex regulatory mechanism that
358 depends on its spatial distribution either in perivascular stroma or endothelial cell
359 compartment. A direct shedding of endoglin from endothelial cell surface inhibits
360 angiogenesis (Hawinkels et al. 2010), whereas the cleavage of LTBP-1 (Dallas
361 et al. 2002; Tatti et al. 2008) or LAP-TGFβ from the stroma in fibrotic tissue
362 increases TGFβ availability which in turn activates TGFβ signaling in vascular cells
363 (Sato 1995; Sounni et al. 2010a). An additional level of complexity comes from the
364 regulation of MT1-MMP/TGFβ signaling axis by type I collagen. Type I collagen
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365induces MT1-MMP expression which in turn regulates TGFβ signaling in stromal
366and cancer cells (Gilles et al. 1997; Ottaviano et al. 2006; Shields et al. 2011).
367Altogether these observations highlight the multifunctional feature of MT1-MMP.
368MT1-MMP emerged recently as a key angiomodulator that controls vessel matura-
369tion and/or regression both in normal and pathological conditions.
37014.7 Concluding Remarks and Therapeutic Potentials
371The ECM in vessel wall is no longer seen as a simple scaffold for vascular cells, but
372is now viewed as a dynamic actor in vascular cell signaling and physiology control.
373Deregulation of the balance between ECM synthesis and degradation contributes to
374vascular pathologies and tumor angiogenesis. Recent progresses in MMP implica-
375tion in vascular biology have underlined the multiple functions of these proteases in
376the regulation of vessel functions. MMPs are now recognized as key modulators of
377angiogenesis in different diseases such as cancer (Lafleur et al. 2003; Lopez-Otin
378and Matrisian 2007), AMD (Noel et al. 2007), psoriasis (Suomela et al. 2001),
379diabetic retinopathy (Giebel et al. 2005) and pulmonary oedema (Davey
380et al. 2011). ECM disruption on the arterial wall is likely a main factor in the
381pathogenesis of vascular system (Raffetto and Khalil 2008), as a decrease in
382structural matrix proteins has been demonstrated in atherosclerotic lesions, abdom-
383inal and intracranial aneurysms, and vascular dilatation (Ruigrok et al. 2006;
384Wagsater et al. 2011). It is well accepted that increased macrophage and
385SMC-derived MMP activities have deleterious effects on atherosclerotic plaque
386stability leading finally to plaque rupture (Johnson 2007). MMP12 overexpressed in
387ruptured plaque tissues (Jormsjo et al. 2000) appears as a key target that led to the
388generation of selective MMP inhibitors with the aim to inhibit plaque rupture of
389advanced atherosclerosis lesion (Fic et al. 2011).
390MT-MMPs effects in vessel wall function and integrity is of great interest for the
391delivery of therapeutics in vivo. MT-MMPs are able to modify the tumor physiol-
392ogy and to affect vessel permeability in vivo. At this end, understanding the cellular
393and molecular mechanisms of MTMMPs and their interaction with ECM and non
394ECM molecules, permeability and interstitial fluid pressure of tumor (Sounni
395et al. 2011) will open new targeting opportunities to enhance vascular leakage
396and delivery of therapeutics to tissues where hemodynamics limit efficient drug
397delivery. However, therapeutic benefits derived from ECM degrading enzyme
398inhibition may lead to vessel stabilization in cancer and hyper active tissues.
399Particularly, this approach may be beneficial if combined with other target pathway
400inhibitors or cytoxic drugs for cancer treatment. In addition, increased understand-
401ing of regulation and function of cryptic fragments within ECM and their role in the
402control of vascular cell physiology will likely lead to more effective strategies for
403therapy. The complexity of targeting proteolytic enzymes due to their pro- and
404antiangiogenic function in cancer or vascular diseases (Lopez-Otin and Matrisian
4052007), renders targeting cryptic collagen sites a highly selective approach for
14 MMP-Mediated Collagen Remodeling and Vessel Functions
406 regulating angiogenesis. Further investigations are required to understand how
407 basement membrane molecules regulate vessel permeability and leakage in cancer
408 and vascular diseases processes.
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